Pleural Mesothelioma Clinical Trial
Official title:
A Phase II, Prospective, Single Arm Trial of Cadonilimab in Combination With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.
Status | Recruiting |
Enrollment | 38 |
Est. completion date | July 2026 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: 1. Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 3. No previous systemic anti-tumor treatment for advanced/metastatic disease 4. Measurable disease as per mRECIST v1.1 for assessment of response in malignant pleural mesothelioma. 5. Adequate haematological, renal and liver function. Key Exclusion Criteria: 1. Primitive peritoneal, pericardial and tunica vaginalis testis mesothelioma. 2. Active, untreated central nervous system (CNS) metastasis. 3. Use of Chinese herbal medicine or immunomodulatory agents with anti-tumor indications within 14 days prior to the first dose of study treatment. 4. Known active autoimmune diseases. 5. Presence of other uncontrolled serious medical conditions. |
Country | Name | City | State |
---|---|---|---|
China | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate (ORR) | defined as the percentage of participants who achieve a best overall response of complete response or partial response assessed according to mRECIST v1.1 for assessment of response in malignant pleural mesothelioma. | Up to 36 months | |
Secondary | Progression Free Survival (PFS) | defined as the time between the date of first dose of study drug and the date of first documented tumor progression per mRECIST v1.1, or death due to any cause, whichever occurs first. | Up to 36 months | |
Secondary | Disease Control Rate (DCR) | defined as the percentage of participants who achieve a best overall response of complete response, partial response, or stable disease assessed according to mRECIST v1.1 for assessment of response in malignant pleural mesothelioma. | Up to 36 months | |
Secondary | Duration of Response (DoR) | defined as the interval from the date of first documentation of objective response (complete response or partial response, according to the mRECIST v1.1) to the date of first documented tumor progression, or death due to any cause, whichever occurs first. | Up to 36 months | |
Secondary | Overall Survival (OS) | defined as the time between the date of first dose of study drug and the date of death due to any cause. | Up to 36 months | |
Secondary | Adverse Events (AEs) | Up to 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04914897 -
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
|
Phase 2 | |
Recruiting |
NCT05910112 -
Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
|
||
Recruiting |
NCT02588131 -
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
|
Phase 2 | |
Recruiting |
NCT06362369 -
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
|
Phase 1/Phase 2 | |
Completed |
NCT02414945 -
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT05714553 -
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT02585362 -
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
|
N/A | |
Completed |
NCT00299962 -
Gene Therapy for Pleural Malignancies
|
Phase 1 | |
Terminated |
NCT04106973 -
Mesothelioma Early Detection by VOCs
|
||
Not yet recruiting |
NCT06155279 -
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
|
Phase 2 | |
Not yet recruiting |
NCT06416930 -
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT01160458 -
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
|
Phase 2 | |
Completed |
NCT02899195 -
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT04040231 -
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
|
Phase 1 | |
Completed |
NCT04430842 -
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
|
Phase 1 | |
Completed |
NCT04324437 -
eRAPID: Online Symptom Reporting in Lung Cancer
|
N/A | |
Recruiting |
NCT03210298 -
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
|
||
Terminated |
NCT00895648 -
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
|
Phase 2 | |
Completed |
NCT00165516 -
Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate
|
Phase 2 |